EU Agency Warns Of GSK Epilepsy Drug's Vision Risks

Law360, New York (May 31, 2013, 4:28 PM EDT) -- The European Medicines Agency recommended Friday that patients take a GlaxoSmithKline PLC epilepsy drug only as a last resort because of concerns it can impair their vision and discolor their skin, weeks after U.S. regulators warned of the side effects.

Trobalt, which was developed by Valeant Pharmaceuticals International Inc. and is distributed by GSK, should be reserved for patients who cannot tolerate other epilepsy drugs or for whom other drugs do not work, according to the EMA's Committee for Medicinal Products for Human Use.

Some Trobalt...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.